NASDAQ:CASI - CASI Pharmaceuticals, Inc.
$3.57
 $0.06
+1.57%
2:05PM EDT
2019-02-15
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CASI     avg for
industry  
  avg for
sector  
42 stocks weight:  11. 80   0. 00   0. 00  
42 stocks rank:  3. 88 K 1. 86 K 1. 09 K
# analyst opinions:  1. 00   14. 92   14. 43  

quick ratio:  14. 45   5. 37   1. 81  
current ratio:  14. 65   5. 69   2. 19  

target price low:  7. 00   88. 97   117. 82  
target price avg:  7. 00   115. 19   141. 96  
target price high:  7. 00   143. 40   163. 16  
1-yr high:  8. 23   124. 30   142. 77  
last close:  3. 51   101. 85   127. 84  
50-day avg:  3. 85   98. 27   122. 46  
200-day avg:  5. 43   99. 72   122. 70  
1-yr low:  2. 77   78. 19   100. 16  
volume:  143. 98 K 2. 38 M 4. 64 M
50-day avg volume:  336. 75 K 3. 31 M 4. 94 M
200-day avg volume:  440. 92 K 3. 23 M 4. 28 M

1-day return:  2. 63 % 0. 22 % 0. 48 %
this week return:  1. 45 % 1. 77 % 2. 01 %
12-wk return:  -13. 12 % 6. 56 % 3. 33 %
52-wk return:  -5. 56 % -2. 23 % 14. 35 %

enterprise value (EV):  219. 66 M 55. 17 B 104. 51 B
market cap:  334. 45 M 49. 01 B 96. 46 B
EBITDA:  -21. 28 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -10. 32   -91. 79   2. 29  
total debt:  1. 50 M 13. 73 B 16. 57 B
debt/equity:  1. 32   258. 01   110. 73  
net income (common):  -23. 25 M 2. 37 B 3. 58 B

shares outstanding:  95. 29 M 607. 99 M 1. 22 B
shares:  41. 15 M 605. 53 M 1. 15 B
shares short:  5. 11 M 11. 62 M 12. 55 M
shares short prior month:  4. 61 M 11. 95 M 13. 44 M
short ratio:  21. 59   4. 82   3. 10  
short % of float:  10. 33 % 6. 19 % 2. 82 %
total cash/share:  1. 07   12. 02   11. 46  
total cash:  100. 03 M 7. 41 B 7. 37 B
free cash flow:  -26. 74 M 95. 99 M 2. 04 B
operating cash flow:  -14. 23 M 164. 74 M 3. 04 B

book value:  1. 21   14. 43   28. 26  
price/book:  2. 89   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  47. 54 % --- ---
1-yr mean volatility:  0. 14 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 30   3. 03   4. 09  
forward EPS:  -0. 22   4. 33   6. 99  
P/E:  -11. 70   6. 11   26. 91  
forward P/E:  -15. 55   8. 38   10. 48  
PE/G:  3. 29   0. 37   5. 61  
growth:  -3. 56 % 683. 72 % 104. 79 %
earnings high:  -0. 00   1. 27   1. 66  
earnings avg:  -0. 00   1. 01   1. 53  
earnings low:  -0. 00   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -19. 69 % -3. 27 % 3. 81 %
return on equity:  -36. 08 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  1. 11   1. 21   0. 93  
sharpe (1yr):  0. 39   0. 06   0. 98  

held % insiders:  42. 30 % 6. 46 % 3. 21 %
held % institutions:  21. 23 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : CASI
.    + 1.573 =         1.573 :: INITIAL WEIGHT
.  + 251.743 =       253.316 :: inverse volume-to-price addition
.  + 338.426 =       591.742 :: spline projection addition
.  - 180.115 =       411.627 :: poor performance penalty
.    x 1.023 =       421.228 :: one-year gains+dividend factor
.    x 4.057 =      1708.744 :: 13 weeks' performance factor
.    x 1.492 =      2550.281 :: industry recommendation factor
.    x 0.998 =       2545.26 :: return on assets factor
.    x 0.996 =      2536.077 :: return on equity factor
.    x 2.573 =      6524.638 :: current ratio factor
.    x 1.036 =      6762.771 :: quick ratio factor
.    x 1.023 =      6917.617 :: short ratio factor
.    x 2.029 =     14035.405 :: price-to-book factor
.    x 1.003 =     14071.344 :: debt-to-equity factor
.    x 2.097 =     29506.846 :: P/E weight
.    x 0.743 =     21914.469 :: PE/G factor
.    x 1.594 =     34927.785 :: beta factor
.    x 0.395 =     13793.895 :: sharpe factor
.    x 2.116 =     29185.741 :: target low factor
.    x 1.332 =     38886.564 :: target mean factor
.      x 1.1 =     42764.126 :: target high factor
.    x 1.066 =       45570.0 :: industry 12-weeks return
.    x 0.949 =      43246.45 :: "drift" penalty 3 days ago
.    x 0.996 =     43077.849 :: "drift" penalty 5 days ago
.    x 0.994 =     42834.719 :: overall "drift" factor
.    x 0.525 =      22470.67 :: largest single-day jump factor
.    x 0.073 =      1643.794 :: low price factor
.      x 1.0 =      1643.905 :: factor hist industry gain for week 06
.   cubeRoot =        11.802 :: reduced for readability
.                     11.802 :: FINAL WEIGHT for NASDAQ:CASI


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org